KRAS and neoplasm: Both PACCE and CAIRO 2 did not pre-select patients with wild-type K-ras tumours, the US Intergroup study, CALGB 80405, had amended the entry criteria to exclude patients with K-ras mutations and hopefully this would be able to answer definitely whether synergy exists between cetuximab and bevacizumab in wild-type K-ras patients.